Neupulse Revenue and Competitors

Nottingham, uk

Location

N/A

Total Funding

Employee Data

  • Neupulse has 11 Employees.(i)
  • Neupulse grew their employee count by 120% last year.

Neupulse's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
N/A1-86%N/AN/A
#2
$15M185-5%N/AN/A
#3
N/A65377%N/AN/A
#4
N/A16632%N/AN/A
#5
N/A13429%N/AN/A
#6
N/A5426%N/AN/A
#7
N/A23323%N/AN/A
#8
N/A24424%N/AN/A
#9
N/A11025%N/AN/A
#10
N/A17734%N/AN/A
Add Company

What Is Neupulse?

Neupulse is the brand of Neurotherapeutics Ltd.\n\nThe direction of our current research was very much shaped by the feedback we received from individuals with tic disorders and their families.\n\nWhen we asked them for their thoughts on our research priorities we were frequently told that what was really needed was a safe and effective non-drug treatment for tic disorder that could be used outside of the clinic and gave individuals control over their tics. This led directly to us focusing on the use of peripheral nerve stimulation as a means of bringing about changes in the brain networks associated with the production of tics.\n\nWe demonstrated that delivering rhythmic patterns of mild electrical stimulation to the median nerve at the wrist could be used to increase the power and the synchronicity of the brain oscillations (rhythms) associated with the suppression of movements, and that this type of stimulation was sufficient to dramatically reduce the frequency of tics and remove the urge-to-tic in individuals with tic disorders.\n\nImportantly, we also showed that this type of stimulation did not materially affect the execution of volitional (intentional) movements or impair cognitive functions such as attention.

keywords:N/A

N/A

Total Funding

11

Number of Employees

N/A

Revenue (est)

120%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.4M11-50%N/A
#2
N/A1138%N/A
#3
$1M11-27%N/A
#4
$1.8M120%N/A
#5
$2.4M12-8%N/A